

Исследование снятия психического напряжения и внутреннего восприятия при использовании флоат-терапии у лиц с высокой чувствительностью к тревоге

Джастин С. Фейнштейн, Сахиб С. Хальса, Хун Йе, Обада Аль-Зуби, Армен К. Аревян, Колин Вольраб, Мария К. Пантино, Ласи Дж. Картмелл, У. Кайл Симмонс, Мюррей Б. Штейн и Мартин П. Паулюс

АННОТАЦИЯ

ПРЕДПОСЫЛКИ: Floatation-REST (терапия уменьшением стимуляции окружающей среды), вмешательство, которое ослабляет экстероцептивный сенсорный вклад в нервную систему, в последнее время было обнаружено, что оно уменьшает тревогу состояния в разнообразном клиническом виде с высоким уровнем чувствительности к тревоге (AS). Для дальнейшего изучения этого анксиолитического эффекта в настоящем исследовании были исследованы аффективные и физиологические изменения, вызванные Floatation-REST, и были оценены люди с высоким уровнем AS, которые испытывали какие-либо изменения в осознании внутреннего восприятия, погруженные в среду, не обладающую экстероцептивным ощущением.

МЕТОДЫ: Используя перекрёстное исследование, 31 участник с высоким AS были случайным образом назначены для прохождения 90-минутной сессии Floatation-REST или сенсорной депривации. Меры самоанализируемого аффекта и интероцептивного восприятия были собраны до и после каждой сессии, и артериальное давление измерялось во время каждой сессии.

РЕЗУЛЬТАТЫ: Floatation-REST генерирует значительный анксиолитический эффект, характеризующийся снижением состояния тревоги и мышечного напряжения, а также увеличением чувства расслабления и безмятежности ($p < .001$ для всех переменных). Значительное снижение артериального давления было очевидным на протяжении всей флоатсессии и достигло самой низкой точки во время фазы диастолы (среднее снижение .12 мм рт. Ст.). Окружающая среда также значительно повысила осознанность и внимание к сердечно-дыхательным ощущениям.

ВЫВОДЫ: Floatation-REST индуцировало состояние расслабления и повышенное интероцептивное восприятие в клиническом виде с высоким AS. Парадоксальный характер анксиолитического эффекта в этом виде обсуждается в связи с теорией обратного торможения Уолпа и регуляцией дистресса с постоянным вниманием к текущим моментам висцеральных ощущений, таких как дыхание.

Keywords: Anxiety, Blood pressure, Floatation-REST, Floating, Interoception, Mindfulness, Novel intervention, Relaxation response

<https://doi.org/10.1016/j.bpsc.2018.02.005>

Anxiety sensitivity (AS) refers to one's fear of experiencing anxiety-related symptoms and sensations, especially those arising from within the body (1). Individuals with high AS often believe that these sensations can lead to adverse consequences, such as death, insanity, or social rejection. Such catastrophic misinterpretations make AS an anxiety amplifier; individuals with high AS are easily alarmed by anxiety-related sensations, and exposure to such sensations often further intensifies their anxiety (1). For this reason, AS has been referred to as a fundamental fear distinct from derivative ones such that the fear of anxiety can provide a motive for avoiding any stimulus likely to incite anxious symptoms (2). Consequently, most cases of chronic anxiety—including panic disorder, agoraphobia, generalized anxiety disorder, social anxiety disorder, and posttraumatic

stress disorder—also feature high levels of AS, making AS a core construct underlying the initiation and maintenance of pathological anxiety (3,4).

Recent evidence suggests that reducing AS may be important for the prevention and treatment of anxiety across diagnostic categories. Prospective studies have shown that AS is a strong predictor for the onset of mood and anxiety disorders and the development of spontaneous panic attacks (1,5,6), whereas longitudinal studies have shown that individuals with high AS have a propensity for greater chronicity of illness and a higher likelihood of experiencing future anxiety symptoms (3,7,8). Controlled studies have shown significant reductions in AS following successful treatment with psychotherapy (9) or pharmacotherapy (10), and several transdiagnostic treatments have been developed to specifically target AS using different forms of

interoceptive exposure (11–14). Taken together, this evidence supports the notion that AS is a fundamental driver of anxiety, and treatments that target AS have the potential of helping patients overcome anxiety regardless of their specific anxiety diagnosis (11).

Our laboratory has recently started to investigate a novel intervention for anxiety that may be beneficial for patients with high levels of AS. Referred to as Floatation-REST (Reduced Environmental Stimulation Therapy), the procedure entails floating supine in a shallow pool of water saturated with magnesium sulfate (Epsom salt). The float experience is calibrated so that sensory signals from visual, auditory, olfactory, gustatory, thermal, tactile, vestibular, gravitational, and proprioceptive channels are minimized, as are most movement and speech. Prior research investigating Floatation-REST has mostly focused on healthy populations, with the most consistent finding being decreases in indices of stress and increases in relaxation as measured from before to after the float session (15,16). Thus far, there has been only one controlled study in participants with clinical anxiety, and the findings showed significant reductions in self-reported symptoms of generalized anxiety following 12 sessions of Floatation-REST that was maintained at 6-month follow-up (17). In a recently completed open-label study (18), we recruited a sample of 50 anxious and depressed participants spanning a range of different anxiety and stress-related disorders (including posttraumatic stress disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, and agoraphobia). Participants underwent a single 1-hour session of Floatation-REST, and overall the procedure was well tolerated, with no major safety concerns or adverse events. Regardless of diagnosis, the float experience induced a strong short-term reduction in state anxiety and a substantial improvement in mood. A subgroup analysis revealed that the participants with the highest AS experienced the greatest reduction in anxiety. To follow up on these findings, the current investigation recruited participants with high AS from the initial open-label study to complete a more intensive protocol that included both a comparison condition and concurrent measurement of blood pressure (BP), a key index of the relaxation response (19). Since other transdiagnostic treatments targeting AS feature manipulations that enhance exposure to interoceptive sensations (11–14), we were also interested in exploring whether the float environment altered interoceptive awareness, a construct that surprisingly has not been formally investigated in prior studies of Floatation-REST despite initial anecdotal reports of enhanced cardiac awareness (20) as well as initial experimental evidence of enhanced cardiac control (21). We hypothesized that by removing exteroceptive sensation, Floatation-REST would enhance awareness for interoceptive sensation.

METHODS AND MATERIALS

All study procedures were approved by the Western Institutional Review Board, and all participants provided written informed consent prior to participation. The trial was registered on [ClinicalTrials.gov](https://clinicaltrials.gov) (<https://clinicaltrials.gov/show/NCT03051074>),

and this study is part of a larger project examining the subjective, physiological, and neural effects of Floatation-REST.

Participant Recruitment and Randomization

The current protocol used a within-subject crossover design. Participants who met specific inclusion and exclusion criteria (see [Supplemental Table S1](#) and [Supplement](#)) were randomly assigned ([Supplemental Figure S1](#)) to complete either a 90-minute session of Floatation-REST (referred to as the float condition) or a 90-minute session of an exteroceptive comparator (referred to as the film condition) that entailed watching a nature documentary from the BBC *Planet Earth* series (22). After completion of one condition, participants crossed over to the other condition approximately 1 week later (average time between conditions was 8 days), with both conditions scheduled to occur at the same time of day for each participant. The randomization sequence was predetermined using a 1:1 allocation ratio, and the study used an open-label design with no blinding or concealed allocation. More details about the Floatation-REST intervention and the exteroceptive comparator can be found in the [Supplement](#).

Measures

All self-report measurements were administered electronically to participants via an electronic tablet (Apple iPad). Survey measures were obtained using REDCap (Research Electronic Data Capture; www.project-redcap.org), a secure web-based application for electronic collection and management of research and clinical trial data. Three different types of self-report measures were administered (see [Supplement](#) for specific details about each measure): baseline measures, before and after session measures, and interoceptive measures. The baseline measures assessed each participant's current symptoms and level of functioning during the time period of the study. The before and after measures were collected at two time points, approximately 30 minutes before and after each float or film session, to assess state-related changes in anxiety [primary outcome measure: change score on Spielberger State Anxiety Inventory (23)] and relaxation. At each time point, participants rated how they felt "right now, in the present moment." In contrast, the interoceptive measures were aimed at gathering retrospective data about how participants felt during the actual float or film experience. Participants also completed a short debriefing interview with the experimenter at the end of the float condition to gather more qualitative information about the float experience and assess for adverse reactions. Finally, BP was measured at 10-minute intervals during each float or film session using a wireless and waterproof setup (see [Supplement](#)).

Statistical Analysis

Change scores were computed for all before- and after-session measures, and most analyses were focused on between-session contrasts of the change scores. To be consistent with the range of scores (0–100) on the visual analog scale, each participant's raw score for state anxiety, serenity, and interoceptive attention was first converted into

standardized POMP units [representing the percent of maximum possible for each measure ranging from 0 to 100% (24)]. All measures were analyzed by linear mixed-effects models (LMMs). The LMM included fixed effects of session (float vs. film), time (after vs. before for the before and after measures; 0, 5, 10, 15, 25, 35, 45, 55, 65, and 75 minutes for the BP measures), and session-by-time interactions; a random intercept and/or a random time-slope were considered to account for participant-specific random effects. As all the interoceptive measures were focused on a single period of time (either during the float session or during the film), the LMM applied to these measures included only fixed effects of session. We focused on the session-by-time interactions for all before-session and after-session measures and BP measures, and between-session differences for all interoceptive measures. The *p* values were corrected for multiple comparisons by controlling false discovery rate at a 5% level. For each outcome measure, we also explored the potential effects of different covariates (age; sex; medication status; randomization order; and baseline severity of psychiatric symptoms based on scores from the Overall Anxiety Severity and Impairment Scale, Patient Health Questionnaire nine-item depression scale, and Sheehan Disability Scale), and we report covariates chosen by the Bayesian information criterion at the end of the Supplement. All analyses were performed with RStudio version 1.0.136 (R Foundation for Statistical Computing, Vienna, Austria) with R version 3.3.2, using the R packages *lme4* (version 1.1-14) for LMM and *lmerTest* (version 2.0-33) for calculation of degrees of freedom and *p* values based on the Kenward-Roger method.

RESULTS

Sample Characteristics

There were 31 participants who met inclusion and exclusion criteria (Supplemental Table S1) and underwent Floatation-REST and the exteroceptive comparison condition. All participants met criteria for one or more anxiety disorders; Table 1 provides additional details about subject demographics and baseline level of functioning. The sample spanned the spectrum of different anxiety and stress-related

disorders, with a mix of comorbidities, including generalized anxiety disorder (*n* = 17), social anxiety disorder (*n* = 11), panic disorder (*n* = 9), agoraphobia (*n* = 8), and posttraumatic stress disorder (*n* = 11). Nearly every participant also had comorbid unipolar major depressive disorder (*n* = 29). Two thirds of the participants (*n* = 21) were stably medicated (for 6 weeks or longer) on one or more psychotropic medications, including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors, benzodiazepines, opiates, and tricyclic antidepressants. At baseline (Table 1), most participants were acutely anxious and depressed, with average scores well above the clinical range of severity (Overall Anxiety Severity and Impairment Scale score = 10.0; Patient Health Questionnaire nine-item depression scale score = 11.6). Participants also presented with high levels of AS (average Anxiety Sensitivity Index-3 total score = 28.1) as well as marked impairment in social and occupational functioning (average total disability score on the Sheehan Disability Scale = 14.7).

Safety and Tolerability of Interventions

There were no serious adverse events or major safety concerns arising during or after Floatation-REST. Most participants chose to float for the entire 90-minute duration, with the exception of 5 participants who exited the pool shortly after the music signaling the end of the float session started playing (approximately 85 minutes into the float). All participants completed the 90-minute film.

Overall, participants rated both conditions as being pleasant on a 100-point bipolar valence scale ranging from −50 (extremely unpleasant) to +50 (extremely pleasant). The average valence rating for the float condition was 32.1 (SD 10.8), and the average valence rating for the film condition was 21.6 (SD 18.3), with participants rating the float as significantly more pleasant than the film ($t_{30} = 2.77, p < .01$).

Measures Before and After Floatation-REST

All measures before and after Floatation-REST (Figure 1) showed a significant session-by-time interaction ($p < .001$). More specifically, after the float condition, participants

Table 1. Participant Demographics and Baseline Functioning

Variable	All Participants	Participants First Randomized to Film	Participants First Randomized to Float
Sample Size	31	16	15
Age, Years	39.1 (11.1)	38.2 (11.7)	39.9 (11.0)
Sex, Male/Female	12/19	4/12	8/7
Medicated Subjects	21	9	12
Anxiety Sensitivity (ASI-3)	28.1 (12.3) [23.6, 32.6]	29.4 (14.2) [21.5, 37.3]	26.9 (10.6) [21.2, 32.5]
Anxiety Severity (OASIS)	10.0 (3.8) [8.6, 11.4]	9.5 (4.3) [7.2, 11.9]	10.4 (3.4) [8.6, 12.3]
Depression Severity (PHQ-9)	11.6 (5.5) [9.6, 13.6]	9.9 (5.8) [6.7, 13.2]	13.1 (4.8) [10.5, 15.7]
Level of Disability (SDS)	14.7 (8.0) [11.8, 17.6]	13.2 (8.1) [8.7, 17.7]	16.1 (7.8) [12.0, 20.3]

The total or average scores are presented for each metric. Numbers inside parentheses represent the standard deviation, and numbers inside brackets represent the 95% confidence interval.

ASI-3, Anxiety Sensitivity Index-3; OASIS, Overall Anxiety Severity and Impairment Scale; PHQ-9, Patient Health Questionnaire nine-item depression scale; SDS, Sheehan Disability Scale.




Figure 1. Anxiolytic effect of floatation therapy. $**p < .001$. Error bars represent SEM. PANAS-X, Positive and Negative Affect Schedule-Expanded Form; POMP, percent of maximum possible; STAI, State-Trait Anxiety Inventory; VAS, visual analog scale.

reported substantial reduction in state anxiety and muscle tension and substantial increases in serenity and relaxation. In comparison, after the film condition, participants reported a similar direction of change on these measures, but the magnitude of change was significantly smaller than the float condition (Figure 1). Further exploration into the muscle tension changes revealed that the reduction in muscle tension while floating was felt most prominently throughout the upper and lower back (Figure 2), although some residual tension remained in the neck. In contrast, the film condition had little effect on muscle tension and seemed to elicit an increase in the number of participants reporting tension in regions of the upper and lower back and gluteus muscles (Figure 2).

Blood Pressure

At baseline, just before beginning the float or film, participants started at a similar level of BP (Figure 3). The float condition, but not the film, induced a reduction in both systolic BP (Figure 3A) and diastolic BP (Figure 3B). The session-by-time interaction was significant for diastolic BP ($p < .001$) but only marginally for systolic BP ($p = 0.13$). Nevertheless, there was still a highly significant main effect of session for systolic BP ($p < .001$). The drop in diastolic BP during the float session was more than twice as large as the drop in systolic BP and occurred more rapidly, evident even at the first measurement taken 5 minutes into the float session (Figure 3B). For both systolic and diastolic measures, BP reductions were most prominent over the first 15 minutes and then tended to plateau throughout the remainder of the float session. The average change from baseline, as calculated across the plateau phase of the float session (15–75 minutes), showed an overall reduction in systolic BP of 5.3 mm Hg and an overall reduction in diastolic BP of 12.8 mm Hg. The 95% confidence interval was computed at each time point that BP was measured (Figure 3), revealing a large spread between values obtained during the float versus film conditions for diastolic BP (Figure 3B). Notably, diastolic BP

was reduced in every participant during the float condition. In comparison, the film condition did not significantly alter BP, with an average drop in systolic of 0.7 mm Hg and an average drop in diastolic of 1.4 mm Hg.

Interoceptive Measures

During the float session, participants reported a significant increase ($p < .001$) in the intensity of cardiorespiratory sensations compared with the film condition (Figure 4A). Likewise, participants also reported a significant increase ($p < .001$) in attention to cardiorespiratory sensations during the float session (Figure 4B) and reported that these sensations felt significantly ($p < .05$) more pleasant while floating than during the film (Figure 4C). Interestingly, the significant increases in interoceptive intensity, attention, and positive valence during the float were specific to cardiorespiratory sensations (i.e., breath and heartbeat) but not gastrointestinal sensations from the stomach and digestive system. Whereas most participants did not feel their heartbeat during the film condition, many reported a clear expansion in where the heartbeat sensation was experienced during the float session, including the chest, ears, eyes, and top of the scalp (Figure 5). On a modified state version of the Multidimensional Assessment of Interoceptive Awareness (25), floating significantly enhanced ($p < .001$) attention regulation (ability to sustain attention on body sensations) and self-regulation (ability to regulate distress by attending to body sensations such as the breath) compared with the film (Figure 6). This pattern of improved self-regulation and heightened interoceptive awareness and attention for cardiorespiratory sensations was also a common theme conveyed by participants during the postfloat debriefing (see the [Debriefing Transcriptions](#) in the [Supplement](#)).

DISCUSSION

There were two main findings in this study: 1) a group of clinically anxious and depressed individuals with high levels of AS experienced a robust relaxation response during and after Floatation-REST that was decisively anxiolytic in nature




Figure 2. Muscle tension tracings. Participants traced any regions where they felt muscle tension. The color scale is filtered to show areas of overlap ranging from 3 to 16 participants.

Floatation-REST and Anxiety Sensitivity




Figure 3. Average (A) systolic and (B) diastolic blood pressure over time in the float and film conditions. Time 0 is baseline. Shaded regions represent the pointwise 95% confidence interval.

(18); and 2) the float environment enhanced interoceptive awareness and attention to cardiorespiratory sensations. For both findings, the effects during Floatation-REST were significantly greater than during the exteroceptive comparison condition. Each of the main findings is discussed in greater detail below.

First, the float environment elicited a relaxation response that was evident both physiologically (via reduced BP) and psychologically (via reduced levels of state anxiety and muscle tension and increased levels of relaxation and serenity). Notably, the relaxation response was significantly larger during Floatation-REST than during the comparison condition, which involved an activity that many people use to help them relax—watching television (in this case a low-arousal pleasant nature documentary from the BBC *Planet Earth* series). As this was every participant's second float session, the significant self-report changes represent a replication of the anxiolytic effect previously observed during the first float session (18), an effect that was similarly characterized by reductions in state anxiety and muscle tension and increases in relaxation and serenity. Interestingly, the magnitude of state anxiety reduction found in the current

study was commensurate with the magnitude of reduction found in the initial float study (with both studies showing an average reduction of approximately 14 points when calculating the before-session to after-session change using the raw total score on the Spielberger State Anxiety Inventory) (18).

This investigation was the first study to measure BP changes during an actual session of Floatation-REST. Although the findings await further replication, they are consistent with previous research showing longer-term reductions in BP following the completion of multiple float sessions (26–29). Future work will need to closely track the temporal course of these BP fluctuations to determine how long the effects last after a float session is over. During the float session, the reduction in BP occurred over the first 15 minutes, eventually reaching a plateau that persisted for the remainder of the session. On average, systolic BP reduced by approximately 5 mm Hg, whereas diastolic BP showed a more pronounced reduction of approximately 13 mm Hg that occurred quite rapidly (often within the first 5 minutes of the float session). Potential factors contributing to the noted reductions in BP are discussed in the Supplement.

The mechanism of action underlying the physiological and psychological changes elicited by Floatation-REST is currently unknown but is likely multifaceted. For example, the reduction in state anxiety is likely a by-product of the float environment, which minimizes exposure to most external triggers of stress and anxiety, providing a chronically anxious and hypervigilant nervous system with a rare respite from the daily barrage of external triggers that it has been sensitized to over the years. The reduction in BP could be related to peripheral vasodilation caused by immersion in the warm water, possibly mediated through relaxation of vascular smooth muscles (see Supplement). Likewise, relaxation of skeletal muscles and the concomitant reduction in both muscle tension and movement is likely related to the water density (calibrated to a specific gravity of approximately 1.26 to suspend the body in a state of neutral buoyancy, where approximately half of the body is floating above the surface of the water and the other half is submerged under the water). The reduction in muscle tension, especially in the upper and lower back, was one of the more prominent effects found in this study and could play an important role in the positive benefits derived from Floatation-REST. Consistent with this notion, a recent investigation found that musculoskeletal pain was the most commonly reported somatic symptom across all types of depressive and anxiety disorders (30), and it remains possible that Floatation-REST is uniquely suited to address these somatic issues.

Second, with regard to interoception, the data suggest that being immersed in an environment lacking exteroceptive sensation does seem to alter the experience of interoceptive sensation, leading present moment visceral sensations to emerge at the center of conscious experience during Floatation-REST. This floatation-induced internal sensory enhancement appeared to show some degree of specificity for cardiorespiratory visceral sensations, whereas gastrointestinal sensations from the stomach and digestive system were not enhanced. More specifically, the float environment seemed to reflexively increase the intensity for, and attention to, interoceptive sensations related to the breath and heartbeat




Figure 4. Interoception ratings during the float (solid bars) and film (hatched bars) conditions. Error bars represent SEM. Ratings of **(A)** intensity, **(B)** attention, and **(C)** valence are shown for three different visceral systems. * $p < .05$; ** $p < .001$. POMP, percent of maximum possible.

(Figure 4). These findings are notable, especially since most individuals, including experienced meditators, show relatively poor interoceptive awareness for cardiac sensation under resting conditions (31,32). Although individuals with high AS do tend to have heightened interoceptive awareness (33,34), it is worth emphasizing that the aforementioned enhancement effects cannot be fully attributed to a global increase in interoceptive awareness in this sample, as these same participants did not report any enhancement during the film condition. Given the heightened AS in this sample and the heightened awareness of cardiorespiratory sensations, it is notable that these sensations were rated as pleasant (Figure 4C), a finding that surprised a number of participants who were used to associating cardiorespiratory sensations with the feeling of anxiety (see *Debriefing Transcriptions* in the Supplement).

The current results present a paradox, as one might expect individuals with high AS to find the heightened experience of interoceptive sensations to be anxiety inducing (rather than reducing). Indeed, years of conditioning have linked interoceptive sensations to the experience of anxiety (35,36), and in the case of AS, this conditioning process can quickly go awry, triggering a pervasive pattern of avoidance that often culminates in one or more of the anxiety disorders. This brings forth the question as to why patients with high levels of AS would find serenity in an environment that enhances awareness for visceral systems previously linked to anxiety. Perhaps one answer to this paradoxical question is encapsulated by Wolpe's seminal theory on reciprocal inhibition, premised on the notion that it is physiologically implausible for the nervous system to be in a state of anxious arousal and a state of relaxation at the same time (37). Wolpe's theory can be summarized as follows: "If a response antagonistic to anxiety can be made to occur in the presence of anxiety-evoking stimuli so that it is accompanied by a complete or partial suppression of the anxiety responses, the bond between these stimuli and the anxiety responses will be weakened" (37, p. 71). Building on this theory, the findings presented here suggest that

Floatation-REST may shift the nervous system into a physiologically quiescent state, one that is antagonistic to anxiety. At the same time, the float environment appears to enhance awareness for visceral systems intimately linked with the experience of anxiety. The emerging clinical effect, however, appears to be one of anxiety reduction, evident in individuals with a range of different anxiety and stress-related disorders who all share the common feature of AS. In cases of high AS, it is possible that part of the anxiolytic effect induced by Floatation-REST stems from reciprocal inhibition, whereby the bond between visceral sensations and anxiety is weakened, and a competing association is formed, one that links the experience of visceral sensations with a state of relaxation instead of anxiety. Thus, if Wolpe's theory holds true, Floatation-REST may not only lead to short-term reductions in




Figure 5. Heartbeat sensation tracings. Participants traced any regions where they felt their heartbeat. The color scale is filtered to show areas of overlap ranging from 3 to 16 participants.




Figure 6. Average score (range, 0–5) on the attention regulation and self-regulation subscales of the Multidimensional Assessment of Interoceptive Awareness. Error bars represent SEM. ** $p < .001$.

anxiety, but also, over time and with repeated exposure, the practice may lead to long-term reductions in AS.

Limitations and Future Directions

Although this study used a within-subject randomized controlled design, replication in a larger sample, with longitudinal follow-up, and a more active comparator will be critical next steps for assessing the anxiolytic efficacy of Floatation-REST. Given that all participants completed an initial float session before this study, the current results may be affected by demand characteristics and biased responses stemming from the first float session. The film comparator used in the current study employed exteroceptive audiovisual stimulation while participants sat upright in a chair, features that likely magnified the differences between conditions on measures of interoceptive awareness and muscle tension. In addition, the current study was limited by its focus on acute effects following a single float session, and it will be imperative to explore the cumulative effects of multiple float sessions in anxious populations to determine whether there is evidence for sustained long-term benefit (17) or signs of adverse effects. In addition, very little is known about how long the acute effects persist after a float is over, and a better understanding for the duration of the acute effects will help determine other factors, such as the optimal “dose” and frequency of floating. Beyond BP, it will be important to also explore other physiological (e.g., heart rate variability and respiration) and neural (e.g., electroencephalography and/or functional magnetic resonance imaging) parameters to have a more complete understanding of how Floatation-REST affects the nervous system. Likewise, the interoceptive measures in the current study were derived via self-report, and future studies should employ behavioral paradigms for more objectively assessing interoceptive accuracy.

The enhancement of awareness and attention for cardio-respiratory sensations during Floatation-REST occurred

without explicit mindfulness instruction or training. The seemingly reflexive nature of the interoceptive enhancement provided by the float environment may have important therapeutic implications, as the cultivation of present moment awareness via sustained attention to the breath is a fundamental feature of many meditative traditions (38,39). Although the practice of meditation appears to help reduce anxiety (40), the effects are often of a small to medium size (41,42), with many acutely anxious patients finding it difficult to sustain their focus on present moment sensations (43). In this light, the float environment may help anxious individuals anchor their attention onto internal sensations such as the breath, both by extreme filtering of all external sensory distractors and stressors and by enhancing the feeling of the heartbeat and the breath. The data further suggest that Floatation-REST may help bolster self-regulation and the reduction of anxiety and distress through sustained attentional focus on present moment body sensations (Figure 6), highlighting the conducive nature of the float environment for facilitating the learning of core skills involved in the training of mindfulness (44). Future research should further explore these preliminary findings to determine whether Floatation-REST facilitates the practice of mindfulness and whether the combination of floating with specific mindfulness instructions can lead to even greater anxiolytic effects.

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the William K. Warren Foundation, Epsom Salt Council (JSF), and National Institutes of Health Centers of Biomedical Research Excellence Grant No. 1P20GM121312.

We thank Colin and Gini Stanwell-Smith of Floataway, who customized and built our floatation pool, and Caylee Winterberg for her help transcribing the debriefing interviews.

The funders of this study and Floataway had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. ACA is founder of Insight Health Systems, Arevian Technologies Inc., and Open Science Initiative. MBS has been a consultant for Actelion, Dart NeuroScience, Janssen, Neurocrine Biosciences, Oxeia Biopharmaceuticals, Inc., Pfizer, Resilience Therapeutics, Inc., and Tonix Pharmaceuticals. The other authors report no biomedical financial interests or potential conflicts of interest.

ClinicalTrials.gov: Examining the Effects of Reduced Environmental Stimulation on Anxiety; <https://clinicaltrials.gov/ct2/show/NCT03051074>; NCT03051074.

ARTICLE INFORMATION

From the Laureate Institute for Brain Research (JSF, SSK, HY, OAZ, CW, MKP, WKS, MPP); Oxley College of Health Sciences (JSF, SSK, LJC, WKS), University of Tulsa; Gallogly College of Engineering (OAZ), University of Oklahoma, Tulsa, Oklahoma; Department of Psychiatry and Biobehavioral Sciences (ACA), University of California Los Angeles, Los Angeles; and Department of Psychiatry (MBS), University of California San Diego, La Jolla, California.

Address correspondence to Justin S. Feinstein, Ph.D., Laureate Institute for Brain Research, 6655 South Yale Avenue, Tulsa, OK 74136; E-mail: feinstein.float@gmail.com.

Received Oct 16, 2017; revised and accepted Feb 22, 2018.

Supplementary material cited in this article is available online at <https://doi.org/10.1016/j.bpsc.2018.02.005>.

REFERENCES

1. Taylor S (2014): *Anxiety Sensitivity: Theory, Research, and Treatment of the Fear of Anxiety*. New York: Routledge.

2. McNally RJ (2002): Anxiety sensitivity and panic disorder. *Biol Psychiatry* 52:938–946.
3. Naragon-Gainey K (2010): Meta-analysis of the relations of anxiety sensitivity to the depressive and anxiety disorders. *Psychol Bull* 136:128–150.
4. Olatunji BO, Wolitzky-Taylor KB (2009): Anxiety sensitivity and the anxiety disorders: A meta-analytic review and synthesis. *Psychol Bull* 135:974–999.
5. Maller RG, Reiss S (1992): Anxiety sensitivity in 1984 and panic attacks in 1987. *J Anxiety Disord* 6:241–247.
6. Telch MJ, Rosenfield D, Lee HJ, Pai A (2012): Emotional reactivity to a single inhalation of 35% carbon dioxide and its association with later symptoms of posttraumatic stress disorder and anxiety in soldiers deployed to Iraq. *Arch Gen Psychiatry* 69:1161–1168.
7. Schmidt NB, Zvolensky MJ, Maner JK (2006): Anxiety sensitivity: Prospective prediction of panic attacks and Axis I pathology. *J Psychiatr Res* 40:691–699.
8. Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, *et al.* (2007): Robust dimensions of anxiety sensitivity: Development and initial validation of the Anxiety Sensitivity Index-3. *Psychol Assess* 19:176–188.
9. Smits JA, Berry AC, Tart CD, Powers MB (2008): The efficacy of cognitive-behavioral interventions for reducing anxiety sensitivity: A meta-analytic review. *Behav Res Ther* 46:1047–1054.
10. Simon NM, Otto MW, Smits JA, Nicolaou DC, Reese HE, Pollack MH (2004): Changes in anxiety sensitivity with pharmacotherapy for panic disorder. *J Psychiatr Res* 38:491–495.
11. Boswell JF, Farchione TJ, Sauer-Zavala S, Murray HW, Fortune MR, Barlow DH (2013): Anxiety sensitivity and interoceptive exposure: a transdiagnostic construct and change strategy. *Behav Ther* 44:417–431.
12. Deacon BJ, Lickel JJ, Possis EA, Abramowitz JS, Mahaffey BG, Wolitzky-Taylor K (2012): Do cognitive reappraisal and diaphragmatic breathing augment interoceptive exposure for anxiety sensitivity? *J Cogn Psychother* 26:257–269.
13. Smits JA, Berry AC, Rosenfield D, Powers MB, Behar E, Otto MW (2008): Reducing anxiety sensitivity with exercise. *Depress Anxiety* 25:689–699.
14. Worden BL, Davis E, Genova M, Tolin DF (2015): Development of an anxiety sensitivity (AS) intervention for high-AS individuals in substance use disorders treatment. *Cogn Ther Res* 39:343–355.
15. van Dierendonck D, Te Nijenhuis J (2005): Floatation restricted environmental stimulation therapy (REST) as a stress-management tool: A meta-analysis. *Psychol Health* 20:405–412.
16. Suedfeld P, Ballard EJ, Murphy M (1983): Water immersion and floatation: From stress experiment to stress treatment. *J Environ Psychol* 3:147–155.
17. Jonsson K, Kjellgren A (2016): Promising effects of treatment with floatation-REST (restricted environmental stimulation technique) as an intervention for generalized anxiety disorder (GAD): A randomized controlled pilot trial. *BMC Complement Altern Med* 16:108.
18. Feinstein JS, Khalsa SS, Yeh H, Wohlrab C, Simmons WK, Stein MB, *et al.* (2018): Examining the short-term anxiolytic and antidepressant effect of Floatation-REST. *PLoS One* 13:e0190292.
19. Benson H (1993): The relaxation response. In: Goleman D, Gurin J, editors. *Mind Body Medicine: How to Use Your Mind for Better Health*. New York: Consumer Reports, 233–257.
20. Shurley JT (1960): Profound experimental sensory isolation. *Am J Psychiatry* 117:539–545.
21. Turner J, Fine T (1985): Effects of restricted environmental stimulation therapy (REST) on self-control of heart rate. In: Sanchez-Sosa JJ editor. *Health and Clinical Psychology*. New York: Elsevier, 477–490.
22. Attenborough D, Fothergill A (2006): *Planet Earth: Complete BBC Series [DVD]*. London: British Broadcasting Corporation.
23. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs G (1983): *State-trait anxiety inventory for adults*. Menlo, CA: Mind Garden.
24. Cohen P, Cohen J, Aiken LS, West SG (1999): The problem of units and the circumstance for POMP. *Multivariate Behav Res* 34:315–346.
25. Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A (2012): The multidimensional assessment of interoceptive awareness (MAIA). *PLoS One* 7:e48230.
26. Jacobs GD, Heilbronner RL, Stanley JM (1984): The effects of short term floatation REST on relaxation: A controlled study. *Health Psychol* 3:99–112.
27. Fine TH, Turner JW (1982): The effect of brief restricted environmental stimulation therapy in the treatment of essential hypertension. *Behav Res Ther* 20:567–570.
28. Turner JW, Fine T, Ewy G, Sershen P, Freundlich T (1989): The presence or absence of light during floatation restricted environmental stimulation: Effects on plasma cortisol, blood pressure, and mood. *Appl Psychophysiol Biofeedback* 14:291–300.
29. Turner JW Jr, Fine TH, McGrady A, Higgins JT (1990): Effects of bio-behaviorally assisted relaxation training on blood pressure and hormone levels and their variation in normotensives and essential hypertensives. In: Suedfeld P, Turner JW, Fine TH, editors. *Restricted Environmental Stimulation. Recent Research in Psychology*. New York: Springer, 184–201.
30. Bekhuis E, Boschloo L, Rosmalen JG, Schoevers RA (2015): Differential associations of specific depressive and anxiety disorders with somatic symptoms. *J Psychosom Res* 78:116–122.
31. Khalsa SS, Rudrauf D, Damasio AR, Davidson RJ, Lutz A, Tranel D (2008): Interoceptive awareness in experienced meditators. *Psychophysiology* 45:671–677.
32. Khalsa SS, Lapidus RC (2016): Can interoception improve the pragmatic search for biomarkers in psychiatry? *Front Psychiatry* 7:121.
33. Domschke K, Stevens S, Pfleiderer B, Gerlach AL (2010): Interoceptive sensitivity in anxiety and anxiety disorders: An overview and integration of neurobiological findings. *Clin Psychol Rev* 30:1–11.
34. Stewart SH, Buffett-Jerrott SE, Kokaram R (2001): Heartbeat awareness and heart rate reactivity in anxiety sensitivity: A further investigation. *J Anxiety Disord* 15:535–553.
35. Paulus MP, Stein MB (2006): An insular view of anxiety. *Biol Psychiatry* 60:383–387.
36. Paulus MP (2013): The breathing conundrum—interoceptive sensitivity and anxiety. *Depress Anxiety* 30:315–320.
37. Wolpe J (1958): *Psychotherapy by Reciprocal Inhibition*. Stanford: Stanford University Press.
38. Hölzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U (2011): How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. *Perspect Psychol Sci* 6:537–559.
39. Van Dam NT, van Vugt MK, Vago DR, Schmalzl L, Saron CD, Olendzki A, *et al.* (2018): Mind the hype: A critical evaluation and prescriptive agenda for research on mindfulness and meditation. *Perspect Psychol Sci* 13:36–61.
40. Miller JJ, Fletcher K, Kabat-Zinn J (1995): Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. *Gen Hosp Psychiatry* 17:192–200.
41. Goyal M, Singh S, Sibinga EM, Gould NF, Rowland-Seymour A, Sharma R, *et al.* (2014): Meditation programs for psychological stress and well-being: A systematic review and meta-analysis. *JAMA Intern Med* 174:357–368.
42. Goldberg SB, Tucker RP, Greene PA, Davidson RJ, Wampold BE, Kearney DJ, *et al.* (2018): Mindfulness-based interventions for psychiatric disorders: A systematic review and meta-analysis. *Clin Psychol Rev* 59:52–60.
43. Strauss C, Cavanagh K, Oliver A, Pettman D (2014): Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder: A meta-analysis of randomised controlled trials. *PLoS One* 9:e96110.
44. Bornemann B, Herbert BM, Mehling WE, Singer T (2015): Differential changes in self-reported aspects of interoceptive awareness through 3 months of contemplative training. *Front Psychol* 5:1504.

The Elicitation of Relaxation and Interoceptive Awareness Using Floatation Therapy in Individuals with High Anxiety Sensitivity

Supplemental Information

Participant Recruitment

All participants were recruited from a previous study where they underwent a single 60-minute float session (without any physiological measurements) to help acclimate them to the float environment (1). On average, there was a 2-month gap between completing the previous study and the current study. In the previous study, participants were recruited through the Tulsa 1000 (T1000) database maintained at the Laureate Institute for Brain Research (LIBR) using specific inclusion and exclusion criteria (Table S1). The T1000 is a naturalistic study that aims to recruit and longitudinally follow 1000 treatment-seeking individuals from the local community, many of whom have anxiety and/or depression (2). Each participant received the Mini-International Neuropsychiatric Interview (MINI) version 6.0 (3), and all psychiatric diagnoses were confirmed following review of the clinical history by a board-certified psychiatrist.

The specific inclusion and exclusion criteria (Table S1) for recruiting participants from the T1000 database into the initial float study targeted individuals with very high levels of AS (defined as an Anxiety Sensitivity Index (ASI-3) total score ≥ 30) across the spectrum of different anxiety and stress-related disorders, many with comorbid unipolar depression. Participants were invited back to participate in the current study so long as they continued to present with at least a mild to moderate degree of anxiety severity during the initial float study, defined as an Overall Anxiety Severity and Impairment Scale (OASIS) score ≥ 6 . From the original 50 participants in the initial float study, 43 were

invited to participate in the current study (Figure S1) which took place during the first half of 2017. Both the ASI-3 and OASIS were re-administered at the start of this study, and the updated scores are presented in Table 1. Since the T1000 is a naturalistic study based on a community sample, we allowed participants who were stably medicated into the study. However, we added exclusion criteria for more severe forms of psychopathology and substance use in order to minimize potential safety risks.

Table S1. Inclusion and Exclusion Criteria for the Initial Float Study

Inclusion Criteria	Exclusion Criteria
1. DSM-IV diagnosis on the MINI of an Anxiety Disorder (Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia) and/or Posttraumatic Stress Disorder (PTSD) 2. Overall Anxiety Severity and Impairment Scale (OASIS) score ≥ 8 3. Anxiety Sensitivity Index (ASI-3) total score ≥ 30 4. If taking medication, must be stably medicated prior to participation (defined as having taken the medication for 6 weeks or longer) 5. Between 18-55 years of age 6. No prior Floatation-REST experience	1. Comorbid Bipolar Disorder or Schizophrenia 2. Active suicidality with intent or plan 3. Currently receiving inpatient treatment 4. Current Substance Use Disorder $\geq$ moderate 5. History of neurological conditions (e.g., epilepsy, stroke, severe traumatic brain injury, Parkinson's disease, Alzheimer's disease or other forms of dementia) 6. Any skin conditions or open wounds that could cause pain when exposed to saltwater 7. Inability to swim or lay comfortably in a shallow pool of water

Floatation-REST Intervention

All float sessions occurred in an open circular fiberglass pool custom-designed for research purposes by Floataway (Norfolk, United Kingdom). The open circular float pool was 8 feet in diameter and contained 11 inches of reverse osmosis water saturated with ~1,800 pounds of USP grade Epsom salt (magnesium sulfate), creating a dense salt

water solution maintained at a specific gravity of ~1.26, allowing participants to effortlessly float on their back. Since the pool had no enclosure, participants could freely enter and exit at any time. The room around the pool was constructed to be waterproof, soundproof, lightproof, and temperature-controlled (described in greater detail below). Silent heaters were placed under the pool to maintain the water at a constant temperature and a dedicated heating, ventilation, and air conditioning system maintained the air at a constant temperature. The temperature of the water and air approximated the surface temperature of the skin (~95.0°F), and could be adjusted remotely by the experimenter in a nearby control room. An intercom system allowed the participant to freely communicate with the experimenter throughout the float session should any issues arise, and specialized speakers placed around the perimeter of the pool allowed the experimenter to communicate with the participant and play music to signal the end of the session.

The float pool and surrounding room were specially engineered to minimize all sensory signals from visual, auditory, olfactory, gustatory, thermal, tactile, vestibular, gravitational and proprioceptive channels. Visual stimulation was minimized by building an entry door and gasket system which expunged all sources of outside light. In addition, there were no windows inside the float room, and the adjacent room contained a private bathroom that also had no windows, and no lights (which were automatically shut off during the float itself). Thus, when the entry door to the float room was sealed and the blue LED light inside the pool was turned off, the float room was completely dark. Auditory stimulation was minimized by constructing the float room using multiple layers of sound dampening walls with thick insulation and added soundproofing material, restricting most outside airborne sound from entering the room. Structural sounds transmitted via

vibrations in the floor were minimized by having the float pool rest on a bed of 48 butyl rubber springs, effectively isolating the pool from the building and preventing structure-borne noises from entering the water. Olfactory stimulation was minimized by using only unscented cleaning products and having the participant shower beforehand to help remove body odors. In addition, the water disinfection system used a combination of ultraviolet light and 35% hydrogen peroxide which does not emit any odors during the oxidative process. Gustatory stimulation was minimized by having participants eat several hours before the float, while refraining from eating and drinking during the float. Thermal stimulation was minimized by setting the temperature of the water and the air to closely match the temperature at the surface of the skin, which is typically a few degrees cooler than core body temperature. All temperature sensors were calibrated using a Thermoworks precision thermometer (Utah, USA) certified by the National Institute of Standards and Technology (NIST). Throughout each float session, the water temperature was maintained at 95.0°F ($\pm 0.3^\circ\text{F}$) and the air temperature at the rim of the pool was maintained at 93.5°F ($\pm 0.5^\circ\text{F}$), slightly lower than the water temperature based on the relative humidity in the air. This temperature setting helped minimize the need for thermoregulation while reducing the perceptual boundary between air, body, and water, a unique feature of the float experience. Specific gravity of the water was calibrated using an H-B Instrument Polycarbonate Hydrometer (Pennsylvania, USA), with a specific gravity range of 1.20-1.42 and NIST calibrated to achieve an accuracy within 0.002. The density of the water and salt concentration was maintained at a specific gravity between 1.25-1.26 for all float sessions. The body's immersion in this dense saline solution minimized stimulation from tactile, vestibular, gravitational, and proprioceptive channels

by buffering the body against the forces of gravity and allowing the individual to effortlessly float on their back in a state of stillness. The importance of “stillness” was also emphasized during the pre-float instruction set, further helping to minimize both movement and speech.

All participants were instructed that they could float “for up to 90 minutes” and could stop floating at any time. The following script was read prior to the float session: *“Throughout the day, our brain and body are constantly bombarded by sensory information from the external world. In this study, we aim to understand what happens when you get a chance to disconnect from this constant stimulation by floating in an environment with reduced levels of light and sound, and reduced pressure on the spinal cord. While floating, try to find a place of stillness of both body and mind. You have complete control throughout the experience and can stop at any time. During the float we encourage you stay awake and when the float is over we will turn on some music for you. There is no rush, so please take your time exiting the pool.”* No additional instructions were provided for how participants should spend their time during the float session.

Exteroceptive Comparison Condition

The subjective and physiological changes during Floatation-REST were directly compared to an exteroceptive comparison condition that took place at the same time of day as the float session, and entailed a 90-minute period of audiovisual stimulation that matched the duration of the float session. Three episodes (*Great Plains*, *Jungles*, and *Seasonal Forests*) from the nature documentary Planet Earth (4) were edited into a single film clip. The film contained pleasant and serene scenes of geographic landscapes and

wildlife. Segments that had the potential to elicit intense emotional or physiological responses, such as depictions of violence or mating, were intentionally excluded. The film was presented on a computer monitor (21.5 x 15 inches) with speakers, and participants were seated upright in a stationary chair approximately 30 inches away from the monitor. As in the Floatation-REST condition, participants were encouraged to stay awake during the film and to try to find a place of stillness in order to minimize both movement and speech.

Baseline Measures

Anxiety Sensitivity Index (ASI-3): The ASI-3 is an 18-item questionnaire that has been shown to have good reliability and validity, and improved psychometric properties over the original measures (5). Questions are answered using a 4-point scale and total ASI scores can range from 0 to 72. Normative data collected in a large sample ($n=4,720$) of healthy North Americans indicate a mean ASI-3 total score of 12.8 ($SD=10.6$) (5). A meta-analysis found that patients with anxiety and depression commonly have a total ASI score around 30 (6).

Overall Anxiety Severity and Impairment Scale (OASIS): The OASIS is a 5-item questionnaire that can be used across the different anxiety disorders as a continuous measure of anxiety severity and impairment over the past week (7). Each item is rated on a 5-point scale and the ratings are summed to obtain a total score ranging from 0 to 20. A cut-score of 8 has been shown to correctly classify 87% of individuals as having a current anxiety diagnosis (8).

Patient Health Questionnaire (PHQ-9): The PHQ-9 is a 9-item measure for assessing the severity of depressive symptoms over the past 2 weeks (9). Scores of 1-4 are considered indicative of minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression.

Sheehan Disability Scale (SDS): The SDS assesses how much the respondent's mental health issues are perceived to have affected their daily activities in three functional domains: work/school, social/leisure activities, and family life/home responsibilities (10). Total disability scores range between 0 to 30, with scores ≥ 5 signifying impairment (11). A review of studies using this measure indicated significant impairment in functioning in patients with anxiety disorders, who have mean total disability scores typically ranging between 14-18 (12).

Pre/Post-Measures

Primary outcome measure — State-Trait Anxiety Inventory (STAI-Y State form): The Spielberger State Anxiety Inventory is a widely used 20-item self-report questionnaire designed to assess an individual's level of anxiety at the present moment with total scores ranging from 20-80 (13). The items assess for the presence or absence of current anxiety symptoms, and the measure has been shown to have excellent internal consistency and good convergent and discriminant validity (13).

Serenity scale on the Positive and Negative Affect Schedule - Expanded Form (PANAS-X): The PANAS-X is one of the most commonly used measures of mood, with high internal consistency, and good convergent, discriminant, and construct validity (14, 15). The serenity scale on the PANAS-X has participants rate how *calm*, *relaxed*,

and *at ease* they feel at the present moment using a 5-point Likert-type response scale, ranging from 1 (Very slightly or not at all) to 5 (extremely).

Visual Analogue Scales (VAS): Participants completed several VAS measures where they rated how they currently felt on a 100-point scale that went from 0 (Not at all/None) to 100 (Extremely/The most I have ever felt). Each scale contained a digital slider (always starting at 0) that participants could move along a horizontal axis. The **Relaxation VAS** asked, “How relaxed do you feel right now?” The **Muscle Tension VAS** asked, “How much muscle tension or tightness do you feel right now?” In addition, during the post-float/film period, participants completed a 100-point bipolar valence scale asking, “Overall, how was your float experience?” or “Overall, how was the film?” The scale went from -50 (Extremely Unpleasant) to +50 (Extremely Pleasant), with the slider starting in the middle of the scale at 0 (Neutral).

Interoceptive Measures

As a first step toward assessing changes in interoceptive awareness, each participant completed a series of self-report measures during the post-float and post-film period. The questions separately probed 3 different visceral sensations (breath, heartbeat, and stomach/digestive system), where participants provided retrospective ratings of intensity, attention, and valence. The interoceptive intensity question (“How intensely did you feel your [insert visceral sensation] while floating/watching the film?”) used a VAS ranging from 0 (Not at all/None) to 100 (Extremely/The most I have ever felt). The interoceptive attention question (“During today’s float/film, how often was your attention focused on your [insert visceral sensation]?”) used a Likert-type response scale,

ranging from 1 (Very slightly or not at all) to 5 (The entire time). The interoceptive valence question (“How did your [insert visceral sensation] feel while floating/during the film?”) used a 100-point bipolar scale that went from -50 (Extremely Unpleasant) to +50 (Extremely Pleasant), with the slider starting in the middle of the scale at 0 (Neutral).

Participants also completed a modified version of the Multidimensional Assessment of Interoceptive Awareness (MAIA) (16), adapted with permission from Dr. Wolf Mehling. A recent study used the MAIA to assess for longitudinal changes in interoceptive awareness following 3-months of meditation training involving mindful attention to the breath and other body sensations, and found that the largest improvements in interoceptive awareness occurred on the attention regulation and self-regulation scales of the MAIA (17). In order to minimize measurement burden and focus on the dimensions of interoceptive awareness most relevant to mindfulness training, the current study had participants complete a state version of the attention regulation and self-regulation scales of the MAIA where they were asked to “indicate how often each statement applied to you during the float/film” using the same rating scale as the original MAIA ranging from 0 (Never) to 5 (Always). The attention regulation scale was comprised of 6 questions assessing one’s ability to sustain and control attention to body sensations (e.g., “I could pay attention to my breath without being distracted by things happening around me”). The self-regulation scale was comprised of 4 questions assessing one’s ability to regulate distress by attention to body sensations (e.g., “When I was caught up in thoughts, I could calm my mind by focusing on my body/breathing”). Both scales used the same items as the original MAIA, with the exception of item 13 from the attention regulation scale (“When I am in a conversation with someone, I can pay attention to my

posture”), which was removed since the question pertained to a social experience that was not part of either the float or film condition. An average score for each scale was computed by averaging the ratings from each question.

In order to obtain more qualitative information about the interoceptive changes, participants used a tablet to trace where they topographically felt their heartbeat sensation and muscle tension on a human manikin. This “Somatomap” application has been used in prior publications (18) and was created using the Chorus platform (chorus.semel.ucla.edu), a secure, web-based toolbox that enables individuals to create interactive mobile applications using a simple, visual interface (19). Tracings were provided both before (“Over the past hour, where did you feel your heartbeat?” or “Over the past hour, please draw anywhere that you felt any muscle tension or tightness?”) and after each session (“During the float/film, where did you feel your heartbeat?” or “During the float/film, please draw anywhere that you felt any muscle tension or tightness?”). An overlap heat map for the entire group was generated at each time point to show the distribution of the felt sensation across the body.

At the end of the float portion of the study, each participant completed a short debriefing interview where they were asked, “What was it like to experience internal body sensations like your breath and heartbeat?” All responses were recorded with a digital audio recorder and later transcribed. Due to technical difficulties, one participant’s response was missing. The debriefing transcriptions for the remaining 30 participants can be found below.

Blood Pressure (BP) Measurement

In addition to the self-report measures, the current study also measured BP using a QardioArm wireless BP monitor (Qardio Inc., San Francisco, California, USA), an FDA-cleared automated sphygmomanometer which uses the Oscillometric method to achieve a measurement range of 40-250 mmHg and an accuracy of ± 3 mmHg. The QardioArm has been clinically validated according to ANSI/AAMI/ISO 81060-2:2009 as well as the European Society for Hypertension International Protocol Revision 2010 (20). The BP cuff was positioned approximately 1 inch above the elbow, around the left upper arm, so that it was situated at the same level as the heart. During both conditions, participants were instructed to keep their arms positioned downwards, resting along the side of their body. A LimbO Waterproof Protector (Limbo USA, Portland, Maine, USA) was placed over the BP device in order to prevent water from reaching the QardioArm during the float session. To ensure comparability across conditions, participants also wore the LimbO during the comparison condition. All BP data was wirelessly transmitted in real-time via Bluetooth 4.0 to an iPad tablet located in the adjacent control room. Each BP measurement took 30-60 seconds to complete and was initiated remotely by the experimenter using an application on the iPad. A baseline BP measurement was collected in the seated position following 5 minutes of rest immediately before starting the float/film. Nine additional BP measurements were collected once every 10 minutes during the float/film. Of note, the first 3 measurements acquired during the float/film were taken every 5 minutes in order to provide a higher temporal resolution for any potential BP changes occurring toward the beginning of a session. A small number of measurements (<3% of the total number of measurements) were either missing (due to a temporary loss in

Bluetooth connectivity with the QardioArm) or were excluded if the reading was deemed an outlier based on previous guidelines (21) that recommended excluding all measurements greater than 2 standard deviations from an individual's average BP during the float or film session. In addition, the dataset from one participant's float session and another participant's film session failed to be collected due to a complete loss in Bluetooth connectivity with the QardioArm, leaving 29 complete datasets where every participant had BP data successfully collected in both conditions.

Potential Factors Affecting BP

One potential explanation for the reduction in BP during Floatation-REST could be related to vasodilation caused by the warm 95°F environment. Indeed, a previous study showed a significant reduction in systolic (but not diastolic) BP when sitting in a room heated to 95°F (22), whereas immersion in 97°F water caused significant reductions in both systolic and diastolic BP (23). In contrast, a small sample of subjects immersed in 93°F Dead Sea water (with a specific gravity of 1.19) actually showed a significant increase in BP (24). Another possibility is related to the high quantity of Epsom salt (magnesium sulfate), which might exert an antihypertensive effect if any of the magnesium were to be transdermally absorbed through the water (25). Body position (seated during the film and supine during the float) is another factor that may be contributing to the BP changes, although prior studies directly comparing BP while supine versus sitting have found contradictory results, with some studies showing lower BP while supine (26, 27) and other studies actually showing higher BP while supine (28-30). It will

be important for future studies to ascertain the specific mechanism(s) by which Floatation-REST reduces BP.

Covariates Chosen by the Bayesian Information Criterion (BIC)

For the Pre/Post-measures, in addition to the Session-by-Time interactions, participants who were first randomized to the Film reported higher serenity ($\beta = 11.6$, $t(33.1) = 2.478$, $p = 0.018$), and participants with higher baseline PHQ-9 scores reported more muscle tension ($\beta = 1.7$, $t(49.0) = 3.996$, $p < 0.001$), but neither effect confounded the Session-by-Time interaction (0.0% change in both beta weights). For the interoceptive measures, in addition to the Session effects, participants who were first randomized to the Float condition perceived lower stomach intensity ($\beta = -16.1$, $t(29.0) = -2.292$, $p = 0.029$) and breath attention ($\beta = -0.6$, $t(29.0) = -2.889$, $p = 0.007$). Again, neither variable confounded the Session effects (0.0% changes in beta weights). For blood pressure, no covariates appeared to be associated with the Session or Session-by-Time interactions. No other covariates (age, sex, medication status, randomization order, and baseline severity of psychiatric symptoms) were selected by the BIC.




Figure S1. Flow diagram for study recruitment

Supplemental References

1. Feinstein JS, Khalsa SS, Yeh H, Wohlrab C, Simmons WK, Stein MB, et al. (2018): Examining the short-term anxiolytic and antidepressant effect of Floatation-REST. *PLoS ONE* 13:e0190292.
2. Victor TA KS, Simmons WK, Feinstein JS, Savitz J, Aupperle RL, Yeh H, Bodurka J, Paulus MP (2018): The Tulsa 1000: A naturalistic study protocol for multi-level assessment and outcome prediction in a large psychiatric sample. *BMJ Open* 8:e016620.
3. Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E (1998): The Mini International Neuropsychi-(1998). The Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and CID-10. *Journal of Clinical Psychiatry* 59:22-33.
4. Attenborough D, Fothergill A (2006): Planet Earth: complete BBC Series. *London: British Broadcasting Corporation [DVD Box Set: 5 discs]*.
5. Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, et al. (2007): Robust dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity Index-3. *Psychological assessment* 19:176-188.
6. Naragon-Gainey K (2010): Meta-analysis of the relations of anxiety sensitivity to the depressive and anxiety disorders. *Psychol Bull* 136:128-150.
7. Norman SB, Hami Cissell S, Means-Christensen AJ, Stein MB (2006): Development and validation of an overall anxiety severity and impairment scale (OASIS). *Depression and anxiety* 23:245-249.
8. Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, Chavira DA, et al. (2009): Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). *Journal of affective disorders* 112:92-101.
9. Kroenke K, Spitzer RL, Williams JB (2001): The phq-9. *Journal of general internal medicine* 16:606-613.
10. Sheehan D (1983): Sheehan disability scale. *Handbook of psychiatric measures*:113-115.
11. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997): Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. *The international journal of psychiatry in medicine* 27:93-105.
12. Sheehan KH, Sheehan DV (2008): Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. *International clinical psychopharmacology* 23:70-83.

13. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs G (1983): *State-trait anxiety inventory for adults*. Mind Garden.
14. Watson D, Clark LA, Tellegen A (1988): Development and validation of brief measures of positive and negative affect: the PANAS scales. *Journal of personality and social psychology* 54:1063-1070.
15. Watson D, Clark LA (1999): The PANAS-X: Manual for the positive and negative affect schedule-expanded form.
16. Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A (2012): The multidimensional assessment of interoceptive awareness (MAIA). *PLoS ONE* 7:e48230.
17. Bornemann B, Herbert BM, Mehling WE, Singer T (2015): Differential changes in self-reported aspects of interoceptive awareness through 3 months of contemplative training. *Frontiers in psychology* 5:1504.
18. Hassanpour MS, Yan L, Wang DJ, Lapidus RC, Arevian AC, Simmons WK, et al. (2016): How the heart speaks to the brain: neural activity during cardiorespiratory interoceptive stimulation. *Phil Trans R Soc B* 371:20160017.
19. Arevian AC, O'Hora J, Jones F, Jones A, Booker-Vaughns J, Banner D, et al. (in press): Participatory Technology Development to Enhance Community Resilience. *Ethnicity & Disease*.
20. O'Brien E, Atkins N, Stergiou G, Karpettas N, Parati G, Asmar R, et al. (2010): European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. *Blood pressure monitoring* 15:23-38.
21. Lee D, Farmer A, Swift C, Jackson S (1995): Investigation of ambulatory blood pressure monitoring data editing criteria. *Journal of human hypertension* 9:195-198.
22. Sollers JJ, Sanford TA, Nabors-Oberg R, Anderson CA, Thayer JF (2002): Examining changes in HRV in response to varying ambient temperature. *IEEE engineering in medicine and biology magazine* 21:30-34.
23. Hildenbrand K, Becker BE, Whitcomb R, Sanders JP (2010): Age-Dependent Autonomic changes Following immersion in cool, neutral, and warm water Temperatures. *International Journal of Aquatic Research and Education* 4:127-146.
24. Ish-Shalom N, Better O (1984): Volume regulation in man during neck-out immersion in a medium with high specific gravity (Dead Sea water). *Israel journal of medical sciences* 20:109-112.
25. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, et al. (2016): Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized

Double-Blind Placebo Controlled Trials. *Hypertension*:HYPERTENSIONAHA.116.07664.

26. Cicolini G, Pizzi C, Palma E, Bucci M, Schioppa F, Mezzetti A, et al. (2011): Differences in blood pressure by body position (supine, Fowler's, and sitting) in hypertensive subjects. *American journal of hypertension* 24:1073-1079.
27. Netea RT, Smits P, Lenders JW, Thien T (1998): Does it matter whether blood pressure measurements are taken with subjects sitting or supine? *Journal of hypertension* 16:263-268.
28. Eşer İ, Khorshid L, Yapucu Güneş Ü, Demir Y (2007): The effect of different body positions on blood pressure. *Journal of clinical nursing* 16:137-140.
29. Netea R, Lenders J, Smits P, Thien T (2003): Both body and arm position significantly influence blood pressure measurement. *Journal of human hypertension* 17:459.
30. Sala C, Santin E, Rescaldani M, Cuspidi C, Magrini F (2005): What is the accuracy of clinic blood pressure measurement? *American journal of hypertension* 18:244-248.

Debriefing Transcriptions for the Question:

What was it like to experience internal body sensations like your breath and heartbeat?

The heartbeat was kinda interesting. At first, it kinda was weird. You know, and 'cause when I was little, we lived in a two-story home, and when I would lay there in bed, my heart would scare me. I thought it was someone coming up the stairs. So I've never been a big fan of a heartbeat. But I kinda enjoyed it. Once I got the rhythm of the breathing and the heart and all that kinda stuff. I think I could hear it more being in the pool. And so that just kinda made it easier for me to concentrate on my breathing 'cause I could really hear it.

—Subject 1

It made it a lot easier to focus on them much better. It didn't bother me. I actually—even though I replied, 'No' to your survey, I just didn't want to have to go through and explain all the times that I've tried to do the stupid meditation. Meditation is no fun. It's not easy. And I don't wanna do it! [laughs] But that was much easier! It was much easier, 'cause you're perfectly relaxed. You're not sitting there going, 'Do I gotta sit? Do I gotta lay down?' Like when you try to meditate, a lot of times, it's kinda like, 'Oh my...' I mean I can't, even for a minute, meditate. Well, and all that is, truthfully, is trying to focus—still your mind and focus on your breath and that kind of thing. Way easier in there!

—Subject 2

I felt like I was just so disconnected. They never even crossed my mind. It was like everything just kinda disappeared. There wasn't really any feeling of anything.

—Subject 3

Helped things slow down even further, going in breathing in the nose, out the mouth. Good. I mean it always feels good to feel it without pain.

—Subject 4

It was great! It was. I carry a lot of tension in my hips, so I was able to breathe and then hear my breath, and actually feel my breath going all the way into those areas. You know, if you just focus on where the tension is or where the pain is, and you just send your breath to that area. And just hearing it like that, it made the experience much more real. Calming. It's calming. It's just a grounding feeling.

—Subject 5

It just seemed like it was more intense. Like the breathing was louder and the heartbeat was louder.

—Subject 6

It wasn't anything spectacular. When I have panic attacks, I can hear my heartbeat really loud so. I mean I could hear it. It wasn't beating as fast as it would if I was having a panic attack. I could just like hear it slowing down and I could control it kind of, sort of.

—Subject 7

A little weird. I really don't like it! It's just really intense. You can hear it a lot louder than after running upstairs. That's why I say it helps if you have a little music [laughs].

—Subject 8

It's calming. Like it's just kinda refreshing 'cause you're not thinking about anything else but the sound. Like that's usually how I calm myself down anyways is to listen 'cause my mom always said, 'Just breathe.' So that's what I do. [laughs]

—Subject 9

Well I was thinking about that beforehand, and you know, I was thinking, you know, my body was pretty noisy. Like I know I'm hungry, my stomach was making growling noise and then, yeah, it's hard for me to kind of notice my heartbeat. You know, I've been asked to do that before and it's kind of like challenging for me, I guess. But I mean I was able to hear it, you know, I don't know, in my ears, and it was almost like a—I don't know, just—and then, yeah, breathing for sure. It didn't bother me at all. I think hearing my heart 'cause it would go through my head, you know, kinda irritated me 'cause it was like a throbbing. Like a, 'Boom! Boom!'

—Subject 10

It was like weird at first, but after a little bit, you kinda get used to it. It was kinda comforting almost.

—Subject 11

It was really weird. [laughs] They were like—I could really—I was acutely aware of my breath. And with my breath, came, you know, a heightened awareness of my heartbeat. So, I kind of was just kind of trying to focus on that quite a bit to kind of like silence the chatter. But it was really kinda neat; kinda weird. I could really hear and feel my breathing sensations.

—Subject 12

Yeah, I kept thinking, 'I wonder if he can hear me breathing. I'm breathing really loud.' [laughs] I can't make my breath stop being so loud. Too much breathing. [laughs]

—Subject 13

That was weird! That was. Because I've done other things and tried to hear it, you know? I could really hear it. I mean, really, I could. I could really hear my breathing. I could hear it, and I could hear my heartbeat and I was like, 'Wow, that is weird.' It's weird 'cause I wasn't trying to. It just did. It was relaxing. At first, it was kinda scary. I think just because so much stress is on me today with the day I was having. At first, I thought I was having a panic attack. But then, I just kinda took over and relaxed and said, you know, 'Just relax. Don't think of anything and just let it.' And it was really neat! I could actually hear my heartbeat and stuff going on in my—it was weird!

—Subject 14

Yeah, even on the survey, I didn't really know how to explain it because it—I really felt and was one with my heartbeat and I could hear it, but it wasn't like the anxiety kind of experience as when I'm having an anxiety or panic attack. So it wasn't a negative thing. It was very in tune with myself kind of feeling. It's a lot different than anxiety and depression. It's more just getting to know yourself; being more in tune. And it's a positive, it is!

—Subject 15

I did also test like breathing through my mouth mostly, or my nose. My nose is kinda stopped up, so I mostly breathed through my mouth. But yeah, I think not having like a lot to look at or hear, my focus was more concentrated on my breathing than normally. I was able to like gauge, you know, how much I was breathing, or how long more so than I would just in a normal day. I kind of liked it. It was nice! I just

felt like more in tune with my body, like more aware of what was going on so that I could react immediately. Like, 'Oh, I'm maybe hungry' or like if my shoulder popped, I could sense where it was and everything. So I enjoyed being a little more aware.

—*Subject 16*

It was definitely more intense, especially when I focused in on my breathing. My heartbeat, I felt that pretty intensely too. So normally, going throughout the day, I don't pay attention to it. I don't notice it. But while being in there, it was very noticeable. My heartbeat was very, very noticeable. I usually don't ever feel my heartbeat during the day. And yeah, I really felt it. And it almost felt like I could hear it also. So it's pretty intense.

—*Subject 17*

It was kinda weird, but it's kinda neat. It was interesting.

—*Subject 18*

It was interesting! You know, hearing my own—you know, I was thinking about, 'Okay, how do my breath sounds sound? Is there anything unusual about them? So I found myself getting distracted by just listening to my own heartbeat and breathing. It was interesting to hear them and not see that my mind just kinda tosses them aside as being essentially, you know, 'Okay, yeah, this is supposed to be there. We need to focus on something else.' That is gonna, you know, be more engaging. So I noticed that, even though I could hear myself breathing. I could hear my, you know, internal pulse, but my heartbeat kinda fell into the background. You know, I could hear it fine if my mind really wanted to find it. But what I found was it pretty much defaulted to being pretty much focused on my respiratory pattern.

—*Subject 19*

It was intense. The breathing was pretty intense. And I was very aware of when I would take that sigh breath. And that was—I mean I know that we do it, but I'm usually not conscious of it. And then my stomach would—or my throat would make little gurgle sounds and I don't really ever hear that. It was interesting 'cause I normally don't pay attention to my breathing. But in the water, you can hear. It's really magnified. But it made me concentrate more on it.

—*Subject 20*

That was pretty cool. And I felt like there was a lot less tension involved with that. It was really weird. There was a point at which I felt like my heartbeat is my whole body moving in the water, like to the rhythm. It's like waves or something. It was pretty cool. It was almost like all over. That feels pretty good!

—*Subject 21*

So my heart was one that was kind of giving me a slight bit of anxiety because, you know, being that still, you can feel everything, and it felt like I may not breathe enough to keep it at a steady rate. [laughs] I was worried about my heart rate going too low. That was really the only thing. I do notice how slow my breathing is! I kind of—I realize, you know, I don't breathe that much when I'm relaxed. I feel like I have to like pay attention to it.

—*Subject 22*

It was very nice! I know a lot of the questions asked about digestive, and I don't think—I apparently am not in tune with my digestive tract. I just don't think about it! But it was neat. I mean being able to hear your heartbeat in your ears. But lots of breath-focusing, counting every progressive muscle relaxation technique that I could think of; kinda went through them all. And being able to do it without really any guilt to go through it 'cause

there was nothing else I was supposed to be doing.

—Subject 23

I think because I'm already probably more aware of it, maybe, then it doesn't distract me or doesn't shock me or it doesn't seem weird or strange. Having the level of anxiety that I have, sometimes, I don't have to be floating in a tank of quietness [laughs] to feel my heartbeat; but it wasn't a panic feeling. It wasn't like noticing that my heart was racing kind of a panic. It was just there, just aware of it. So it wasn't distracting or anything.

—Subject 24

The breathing was crazy 'cause it felt so deep. Like I felt like it wasn't—it was like past my body. Like it was going down and around me. And I felt—like I couldn't tell what part of my body was in the water and what part of my body wasn't in the water. I definitely could feel my whole body take it in and out. And like the heartbeat, because of the blood pressure, that made me realize I was calmer. 'Cause I had a moment, there of stressful craziness, but [laughs] I was like, 'You need to calm yourself down. Just feel it. Feel it through.' So I feel like I felt it more, definitely. Like my heartbeat and breathing.

—Subject 25

Well, you know, really the only thing that I even noticed was my breath. I didn't notice anything else. But then, at some point, I was—I think it might be because of allergies and lying down with my head back—it became difficult to breathe through my nose. So I started through my mouth at some point.

—Subject 26

Normally, I'm pretty good with as far as—I don't do it a lot, but I know about diaphragmatic breathing, and I've done it

before, so I am familiar with that aspect. I don't practice it near as much as I should. As far as heartbeat, that was different! 'Cause I don't really ever—it doesn't really seem like—or feel like my heart or anything—whatever, you know, day-to-day stuff, you know? Unless you've just got done working out or something like that! Whenever I'm out at the pool. Like right now, I couldn't tell you what my heartbeat is at all; but in the pool, it was kinda neat to actually, you know, feel it! Because you can be aware of it! But the breath is good because that's, of course, you have your breathing techniques and diaphragmatic breathing and stuff like that. So that kind of stuff works for me a little better normally. For some reason, like diaphragmatic breathing and some breathing exercises will give me a little bit more anxiety. But this time, not so much. So whenever I'd focus on breathing or whatever—so it was nice.

—Subject 27

Yeah! What's interesting is like I didn't have a lot of like—other than my breath; I noticed that I could feel and hear my breath a lot more if I breathed through my nose. And so I was like, 'Well, I'll just breathe through my mouth so that I don't have to hear it.' Or feel it or whatever! And then, I started to kind of just realize that—I don't know—like I started breathing through my nose—just my nose—and even though I could hear it, it was somehow soothing. And then, that's what led to me being very still and then going into that—I don't know—whatever state it was, yeah. And for whatever reason that—I don't know if that played a role in today, but a couple times, I woke up and my throat was really relaxed—almost too relaxed. And so I had to like make myself breathe deep breaths. It was like I wasn't breathing. It was like I was kind of—I was breathing, but I wasn't breathing strongly, or with purpose. It was

more like—it's hard to explain—it was starting to like almost shut off. So I had to like make myself take a deep breath and then make myself breathe. It happened a couple times.

—*Subject 28*

I wasn't really focused on anything. My mind was completely blank. I didn't really hear my heartbeat too much, but I could feel and hear my breath a lot better. I think that's kind of why I feel so relaxed, 'cause my breathing was a lot more regulated like it should be.

—*Subject 29*

It was kinda neat because I'm so busy and my mind is going so many different places, I don't really notice it as much during the day. And I think I usually think that I have very much social awareness and awareness of my body because I'm so self-conscious a lot of times. But I've found that in the past, there's a lot of times I'm not totally aware. And I will have those reactions that I think I've got it under control [laughs] and really everybody sees it but me. And in there, just being so much more body-aware is just very different for me. The only time I usually notice my heart as much, is when I have very high—you know, my anxiety is pretty high or if I've just walked a flight of stairs, you know? [laughs] It's either the physical or that, you know, anxiety—matter of fact, I've been at the hospital a few times in the past, probably 15 years or so, thinking I was having a heart attack when it was really anxiety. And the weirdest part is my body will mimic these reactions. Like my fingers will tingle, and I think my hand's going numb, and you know, all these just manifestations of this anxiety. It's crazy. You know, I would notice my body some. I could feel my body, but I would be so relaxed, it was almost like, at times, my body was one with the water.

—*Subject 30*